July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Evaluation of the effects of VEGF/ANG-2 neutralization on vascular, neuronal and inflammatory pathologies in a spontaneous choroidal neovascularization (CNV) mouse model
Author Affiliations & Notes
  • Richard H Foxton
    Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland
  • Sabine Uhles
    Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland
  • Sabine Gruener
    Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland
  • Franco Revelant
    Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland
  • Nadine Colé
    Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland
  • Mirjana Lazendic
    Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland
  • Mathieu Brecheisen
    Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland
  • Christoph Ullmer
    Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland
  • Footnotes
    Commercial Relationships   Richard Foxton, Roche (E), Roche (I); Sabine Uhles, Roche (E), Roche (I); Sabine Gruener, Roche (E), Roche (I); Franco Revelant, Roche (E), Roche (I); Nadine Colé, Roche (E), Roche (I); Mirjana Lazendic, Roche (E), Roche (I); Mathieu Brecheisen, Roche (E), Roche (I); Christoph Ullmer, Roche (E), Roche (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 237. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Richard H Foxton, Sabine Uhles, Sabine Gruener, Franco Revelant, Nadine Colé, Mirjana Lazendic, Mathieu Brecheisen, Christoph Ullmer; Evaluation of the effects of VEGF/ANG-2 neutralization on vascular, neuronal and inflammatory pathologies in a spontaneous choroidal neovascularization (CNV) mouse model. Invest. Ophthalmol. Vis. Sci. 2018;59(9):237.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Wet age-related macular degeneration (AMD) and diabetic macula edema (DME) are characterized by vascular hyperpermeability, inflammation, and neuronal loss. We investigated an anti-VEGF/ANG-2 bispecific antibody (Ab) as a potential treatment for these pathologies in a spontaneous model of CNV in JR5558 mice. We administered anti-VEGF, anti-ANG-2, or anti-VEGF/ANG-2 Abs, and measured CNV lesion number/size, vascular permeability, inflammatory cells and retinal apoptosis.

Methods : At postnatal day P45, animals were assigned to equimolar treatment groups: IgG control (10 mg/kg), anti-VEGF (5 mg/kg), anti-ANG-2 (5 mg/kg), or anti-VEGF/ANG-2 (10 mg/kg). Abs were dosed intraperitoneally at P46 and P53. Fluorescein angiography (FFA) and fluorophotometry data were collected at P60. At P61 animals were euthanized for tissue harvesting. Eyes were removed for wholemount TUNEL (retina) and Iba1 (RPE/choroid) staining. TUNEL was performed using a commercial kit for TdT-mediated dUTP-biotin nick end labeling, and Iba1 staining and isolectin B4 counterstain by immunohistochemistry, and quantified by semi-automated analysis. Lesion number/size were assessed in FFA images. Leakage was assessed by fluorophotometry. Statistics were done using one-way ANOVA and post-hoc tests.

Results : There were significant reductions in lesion number/area with anti-VEGF, anti-ANG-2 and anti-VEGF/ANG-2 vs IgG control. There was a further therapeutic effect of anti-VEGF/ANG-2 on lesion area vs anti-VEGF and anti-ANG-2 monotherapy. Iba1 staining revealed reduced macrophages in the subretinal space with anti-VEGF, anti- ANG-2 and anti-VEGF/ANG-2 vs IgG, which was significant for anti-VEGF/ANG-2 only. TUNEL staining data showed that anti-ANG-2 and anti-VEGF/ANG-2 reduced retinal apoptotic nuclei, with the anti-VEGF/ANG-2 treatment showing highest significance (P = 0.011 for anti-ANG2, P = 0.007 for anti-VEGF/ANG-2).

Conclusions : Anti-VEGF/ANG-2 treatment resulted in superior reduction in FFA lesion area, reduced Iba1-positive subretinal macrophages, and decreased apoptosis at higher significance (up to 33%) vs IgG control compared to anti-VEGF or anti-ANG-2 monotherapy. Bispecific anti-VEGF/ANG-2 Ab gives superior efficacy on vascular, neuronal, and inflammatory readouts in JR5558 mice vs monotherapy. Anti-VEGF/ANG-2 is a promising therapy for wet AMD and DME.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×